5% methylcellulose, GK rats, model control), nateglinide
(50 mg/kg, GK rats, positive control) or AA (50 mg/kg, GK rats, sample) by oral gavage twice daily just before each meal for 12 weeks.
On the fifth day of treatment, nateglinide
therapy was discontinued because the two-hour postprandial glucose levels were were found to be between 70 and 80 mg/dl.
Repaglinide (Gluconorm[R]) and nateglinide
(Starlix[R])are both approved to be used in combination with metformin (Novartis Pharmaceuticals, 2009; Novo Nordisk, 2010).
Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycaemia seen in obese, type 2 diabetics: Assessment using Nateglinide
, a new insulin secretagogue.
Medications currently approved to treat type 2 diabetes, 2010 Mean Maximum daily daily Class Drugs doses doses Biguanide Metformin 850 mg (a) 2 550 mg Sulfonylureas Chlorpropamide 250 mg (b) 500 mg Glibenclamide 5 mg (a) 20 mg Glipizide 5 mg (a) 20 mg Glimepiride 4 mg (b) 8 mg Gliclazide 80 mg (a) 320 mg Gliclazide MR 60 mg (b) 120 mg Meglitinides Nateglinide
60 mg (c) 360 mg Repaglinide 2 mg (c) 12 mg Thiazolidinediones Rosiglitazone 4 mg (a) 8 mg Pioglitazone 30 mg (b) 45 mg a-glucosidase Acarbose 50 mg (c) 300 mg inhibitors Miglitol 25 mg (c) 100 mg DPP-4 inhibitors/ Sitagliptin 100 mg (b) 100 mg gliptines Vildagliptin 50 mg (a) 100 mg Saxaglipnin 5 mg (b) 5 mg Incretine analogues Exenatide 20 mcgr (a) 20 mcgr Liraglutide 1.
s Glucovance); and nateglinide
(a generic version of Novartis' Starlix).
Repaglinide (Prandin[R]) and nateglinide
(Starlix[R]) are short-acting nonsulfonylureas or glinides that are only used preprandially (before meals).
In a large medical trial, patients with pre-diabetes and patients with cardiovascular risk factors did not respond to nateglinide
, which stimulates insulin secretion in the body.
Additionally, the blood sugar lowering drug nateglinide
(Starlix) proved ineffective at halting progression to diabetes, and had no significant impact on reducing cardiovascular events.
Sulfonylureas, repaglinide, and nateglinide
are insulin secretagogues that stimulate endogenous insulin secretion from the pancreas (Davies, 2002) and are used as hypoglycemic agents for the treatment of type 2 diabetes.
The study assessed whether valsartan or the oral anti-diabetic agent nateglinide
could delay progression to diabetes or reduce the incidence of cardiovascular events in people with IGT and cardiovascular disease or risk factors.
Improved prandial glucose control with lower risk of hypoglycemia with nateglinide
than with glibenclamide in patients with maturity-onset diabetes of the young type 3.